Bayer backs Iberogast against safety attacks
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Bayer Consumer Health has defended its decision not to include warnings about possible liver-damage when taking its herbal gastrointestinal product Iberogast, after harsh criticism from German Member of Parliament (MP) Kordula Schulz-Asche.
You may also be interested in...
Bayer Stands By Iberogast As German Court Investigates Manslaughter Case
Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.